loading page

Emerging role of cysteinyl leukotrienes in cancer
  • Lou Saier,
  • Olivier Peyruchaud
Lou Saier

Corresponding Author:lou.saier@inserm.fr

Author Profile
Olivier Peyruchaud
Author Profile


Cysteinyl leukotrienes (CysLTs) are inflammatory lipid mediators that play a central role in the pathophysiology of several inflammatory diseases. Recently, there has been an increased interest in determining how these lipid mediators orchestrate tumor development and metastasis through promoting a pro-tumoral microenvironment. Upregulation of CysLTs receptors and CysLTs production is found in a number of cancers and has been associated with increased tumorigenesis. Understanding the molecular mechanisms underlying the role of CysLTs and their receptors in cancer progression will help investigate the potential of targeting CysLTs signaling for anti-cancer therapy. This review gives an overview of the biological effects of CysLTs and their receptors, along with current knowledge of their regulation and expression. It also provides a recent update on the molecular mechanisms that have been postulated to explain their role in tumorigenesis and on the potential of anti-CysLTs in the treatment of cancer.
07 Sep 2020Submitted to British Journal of Pharmacology
09 Sep 2020Submission Checks Completed
09 Sep 2020Assigned to Editor
17 Sep 2020Reviewer(s) Assigned
03 Nov 2020Review(s) Completed, Editorial Evaluation Pending
10 Nov 2020Editorial Decision: Revise Minor
28 Dec 20201st Revision Received
30 Dec 2020Submission Checks Completed
30 Dec 2020Assigned to Editor
31 Dec 2020Reviewer(s) Assigned
23 Jan 2021Review(s) Completed, Editorial Evaluation Pending
24 Jan 2021Editorial Decision: Accept
02 Feb 2021Published in British Journal of Pharmacology. 10.1111/bph.15402